Specialty Pharmaceuticals: Solving the Encore Problem
This article was originally published in Start Up
Executive SummaryEven the most successful specialty pharmas hit a point where an in-licensing candidate has to be almost too costly in order to sustain the growth of the organization. Start-ups are trying to avoid this trap by developing capabilities that add significant value to an in-licensing candidate, or by having at the outset some approach to identifying products and niches that no one else can.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.